If you are trying to access this site from the United States, please try heading to our homepage or our drug directory
The International Association for the Study of Pain defines it as pain resulting from a stimulus that does not normally provoke pain, and that definition matters because it distinguishes allodynia from hyperalgesia, where painful stimuli simply hurt more than expected
Retatrutide, also known as LY3437943, is an investigational single-molecule triple agonist studied for activity at the GIP, GLP-1, and glucagon receptors
Retatrutide is dosed weekly in milligrams
At the same time, GLP-/GIP dual agonists may also be an effective treatment option for non-diabetic patients with abnormal lipid metabolism
Possible retatrutide benefits should still be framed as research findings until full review is complete